Amneal Receives Approval for Generic Version of Ortho Evra

Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.

Amneal’s Norelgestromin and Ethinyl Estradiol Transdermal System is the generic version of the reference listed drug (“RLD”) Ortho Evra® and will be marketed under the proprietary name Zafemy™. Zafemy is a 12.5 cm2 patch indicated for the prevention of pregnancy in women with a Body Mass Index of less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Zafemy may be less effective in preventing pregnancy in women at or above 198 lbs (90 kg). The Company expects to begin commercialization activities on March 1, 2021.

“Today’s approval is a significant milestone for patients and our company,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “Zafemy will provide patients with another option to the one equivalent product—Xulane®, manufactured by Mylan—currently on the market. It also demonstrates the continued successful execution of our strategy to develop and commercialize complex generics and represents the 10th of 15 high-value complex products we expect to launch before August 2021.”

According to IQVIA™, a leading healthcare data and analytics provider, U.S. annual sales for Xulane® for the 12 months ended December 2020 were approximately $332 million.

“Zafemy is our fifth transdermal product approval and utilizes our extensive in-house expertise in Matrix-based as well as Hydrogel-based patches,” continued Mssrs. Patel. “We continue to focus our R&D capabilities as well as the power of our integrated supply chain on bringing more complex products to market faster and more cost efficiently.”

The RLD Ortho Evra® has been discontinued, and according to the FDA announcement of discontinuation published in the Federal Register, the product was not discontinued or withdrawn for safety or efficacy reasons. Xulane® is the only other equivalent to Ortho Evra® currently available on the market.

The drug carries a boxed warning regarding cigarette smoking and serious cardiovascular events. Zafemy is contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC), the labeling says. Zafemy is also contraindicated for use in women with a Body Mass Index greater than 30 kg/m2. Women with a BMI greater than 30 kg/m2 may have a higher risk of venous thromboembolic events compared with women with a lower BMI.

The most frequent adverse reactions reported during clinical trials (≥ 5%) were breast symptoms, nausea/vomiting, headache, application site disorder, abdominal pain, dysmenorrhea, vaginal bleeding and menstrual disorders, and mood, affect and anxiety disorders. See Package Insert (PI) for full prescribing information including boxed warning: https://www.amneal.com/wp-content/uploads/2021/02/ZAFEMY-PI-Rev-02-2021-03.pdf

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

For more information, visit www.amneal.com.

SOURCE: Amneal Pharmaceuticals